Myasthenia Gravis

Key Points

• Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes fluctuating weakness in voluntary muscles.
• New symptom onset can be abrupt, but subtle early symptoms may delay diagnosis.
• Autoantibodies block acetylcholine receptor function at the neuromuscular-junction, impairing impulse transmission.
• Weakness typically worsens with repeated activity and improves with rest.
• Respiratory and swallowing muscle involvement can create life-threatening airway risk.
• Distinguishing myasthenic crisis from cholinergic crisis is essential because treatment differs.

Pathophysiology

Myasthenia gravis is an autoimmune disorder in which antibodies target postsynaptic acetylcholine receptor sites at the neuromuscular junction. This receptor blockade reduces effective acetylcholine binding and weakens neuromuscular transmission, producing fatigable muscle weakness.

Normal cholinergic signaling relies on acetylcholine release, receptor binding, and acetylcholinesterase-mediated breakdown to reset the synapse. In myasthenia gravis, disrupted receptor access causes progressive decline in contraction strength during repeated use.

There is also a thymus association: many affected patients have thymic abnormalities, supporting loss of immune self-tolerance as part of disease development.

Classification

• Ocular-predominant pattern: Early ptosis and diplopia from extraocular muscle weakness.
• Generalized pattern: Progressive involvement of bulbar, limb, and respiratory muscles with variable exacerbations and remissions.
• Myasthenic crisis pattern: Acute worsening weakness with respiratory failure from disease exacerbation.
• Cholinergic crisis pattern: Respiratory failure from excess anticholinesterase effect.

Nursing Assessment

NCLEX Focus

Differentiate fatigable weakness that improves with rest from fixed deficits due to structural neurologic injury.

• Assess fluctuation pattern of weakness across the day and after repeated activity.
• Assess ocular findings such as ptosis and diplopia, which are common early findings.
• Assess bulbar manifestations including dysphonia, dysarthria, chewing fatigue, and dysphagia with aspiration risk.
• Assess for reduced facial-expression strength and neck-muscle weakness that can make head support difficult.
• Assess neck, limb, and respiratory muscle weakness because deterioration can rapidly threaten airway safety.
• Assess functional impact on daily activities during exacerbation and remission periods.
• Assess for exacerbation triggers such as intercurrent illness, fever, surgery, emotional stress, pregnancy, and medications that impair neuromuscular transmission.
• Assess for crisis findings: myasthenic crisis may present with tachycardia, hypertension, pale/cool skin, and loss of cough or gag reflex; cholinergic crisis may present with bradycardia, increased secretions, diarrhea, abdominal cramping, and red/warm skin.

Diagnostic and Monitoring Data

• Edrophonium (Tensilon) testing may transiently improve strength in myasthenia gravis; atropine should be immediately available due to potential severe bradycardia or bronchoconstriction.
• EMG may show decremental action potentials with repetitive stimulation.
• Blood testing can identify acetylcholine receptor antibodies.
• CT or MRI can evaluate thymic enlargement.

Nursing Interventions

• Prioritize airway and aspiration-risk surveillance in patients with bulbar or respiratory weakness.
• Monitor cough/deep-breath capability and keep suction and emergency airway equipment at bedside during exacerbations.
• Monitor for respiratory failure and both myasthenic and cholinergic crisis patterns.
• Provide nutritional support with small frequent meals, soft foods, and high-calorie snacks; position upright with chin-down swallowing strategy.
• Cluster care and schedule short activity periods during times of maximal strength.
• Encourage rest to reduce fatigue-triggered worsening.
• Reposition frequently and protect eyes (artificial tears/eye protection) when eyelid closure is impaired.
• Escalate rapidly worsening breathing or swallowing function as emergency deterioration.

Health Teaching

• Emphasize strict medication timing; dosing about 1 hour before meals can improve chewing and swallowing.
• Teach trigger avoidance: infection, surgery, pregnancy stressors, extreme temperatures, and fatigue.
• Teach emergency symptoms and crisis response plan, including when to activate EMS.
• Teach medication cautions for agents that may worsen symptoms (for example selected calcium channel blockers, some antibiotics, and magnesium-containing antacids/laxatives).
• Recommend medical alert identification and communication plans for episodes of severe weakness.
• Reinforce routine health maintenance and vaccination adherence.

Crisis Risk

Acute respiratory weakness can progress to myasthenic crisis and requires immediate escalation.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
cholinesterase-inhibitors	Pyridostigmine, neostigmine	Give on time to maintain stable effect; delayed dosing can worsen weakness.
Immunosuppressants	Corticosteroids, azathioprine, cyclophosphamide	Reduce autoimmune antibody activity; monitor for leukopenia, hepatotoxicity, and infection risk.
anticholinergics	Atropine (cholinergic crisis context)	Reverses excess cholinergic effects in cholinergic crisis and may require repeat dosing.
Antibody-reduction therapy	Plasmapheresis; thymectomy (selected patients)	Used for temporary antibody reduction or long-term autoimmune-load reduction.

Clinical Judgment Application

Clinical Scenario

A patient with known myasthenia gravis develops worsening weakness, dyspnea, and poor secretion clearance.

• Recognize Cues: Progressive respiratory and bulbar weakness with crisis risk.
• Analyze Cues: Distinguish myasthenic versus cholinergic crisis because treatment pathways differ.
• Prioritize Hypotheses: Airway failure is the immediate threat.
• Generate Solutions: Activate emergency response, support ventilation, and prepare focused diagnostic reassessment.
• Take Action: Initiate airway protection, close cardiopulmonary monitoring, and medication review with provider.
• Evaluate Outcomes: Respiratory status stabilizes and aspiration risk decreases.

Related Concepts

• neurological-system - Neurotransmitter and neuromuscular transmission foundations.
• nursing-care-priorities-for-neuromuscular-impairment - Respiratory and mobility-risk prevention in progressive weakness.
• neuromuscular-diagnostic-testing - Electrophysiologic evaluation in neuromuscular disorders.
• dysphagia - Swallowing safety strategies to reduce aspiration risk.
• immune-globulins - IVIG is used in selected autoimmune neuromuscular treatment pathways.

Self-Check

1. Which findings help differentiate myasthenic crisis from cholinergic crisis at bedside?
2. Why does medication timing matter for anticholinesterase therapy in daily symptom control?
3. Which airway and swallowing interventions should be prioritized during exacerbation?